El Hammiri Ayoub, Potvin Jeannot, Gobeil Jean-François, Noiseux Nicolas, Stevens Louis-Mathieu, Masson Jean-Bernard
Division of Cardiology, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Division of Cardiology, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada; Centre de Recherche du CHUM, Montréal, Québec, Canada.
Can J Cardiol. 2017 Apr;33(4):555.e13-555.e15. doi: 10.1016/j.cjca.2016.11.018. Epub 2016 Nov 29.
Valve-in-valve implantation is generally successful in reducing paravalvular regurgitation (PVR) in cases in which the first transcatheter heart valve is deployed in a suboptimal location. We describe a case of severe PVR 2 months after implantation of a 26-mm Sapien XT valve (Edwards Lifesciences Inc, Irvine, CA) in the optimal location. Valve-in-valve implantation of a Sapien 3 valve (Edwards Lifesciences Inc), and enough left ventricular outflow tract tissue at the inflow edge the Sapien XT to appose the sealing cuff of the Sapien 3 combined for successful PVR treatment. To our knowledge, this is the first case of PVR reduction with valve-in-valve despite the original valve being appropriately sized and placed.
在首次经导管心脏瓣膜植入位置欠佳的情况下，瓣中瓣植入通常能成功减少瓣周反流（PVR）。我们描述了一例在最佳位置植入26毫米Sapien XT瓣膜（爱德华兹生命科学公司，尔湾，加利福尼亚州）2个月后出现严重PVR的病例。通过植入Sapien 3瓣膜（爱德华兹生命科学公司）进行瓣中瓣植入，并利用Sapien XT流入边缘足够的左心室流出道组织来贴合Sapien 3的密封套，成功治疗了PVR。据我们所知，这是尽管原始瓣膜尺寸合适且位置恰当，但仍通过瓣中瓣实现PVR减少的首例病例。
